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Abstract 
The zoonotic transmissions of highly pathogenic avian influenza viruses of the H5N1 subtype that occur since 1997 
have sparked the development of novel influenza vaccines. 
The advent of reverse genetics technology, cell culture production techniques and novel adjuvants has improved the 
vaccine strain preparation, the production process and the immunogenicity of the vaccines respectively and would 
accelerated the availability of pandemic influenza vaccines. However, there is still room for improvement and 
alternative vaccine preparations are explored such as recombinant antigens (e.g. baculovirus expression) and viral 
vectors. Modified Vaccinia virus Ankara (MVA), originally developed as a safe smallpox vaccine can be exploited as 
a viral vector. It has favourable properties, which makes it an attractive candidate as a pandemic influenza vaccine  
(for review see reference [1]). Recently we have evaluated a MVA-based vaccine for highly pathogenic influenza 
virus of the H5N1 subtype in mice and macaques. To this end, recombinant MVA was constructed expressing the 
gene encoding the hemagglutinin of H5N1 influenza virus A/Vietnam/1194/04 (clade 1) (MVA-HA-VN/04) and used 
to immunize C57BL/6 mice and cynomolgus macaques (macaca fascicularis). Two immunizations induced strong 
virus specific antibody responses in both species and protected the animals from the development of severe disease 
observed in control animals inoculated with empty MVA vector or PBS after challenge infection with the 
homologous or the antigenically distinct influenza virus A/Indonesia/5/05 (clade 2.1). In vaccinated animals virus 
replication in the respiratory tract was not detectable and the development of histopathological changes in the lungs 
was prevented. Furthermore, a MVA-based 2009 pandemic H1N1 vaccine protected against severe disease in a 
pH1N1 ferret model.  
The preclinical evaluation of MVA-based candidate vaccines indicated that they have potential as vaccines against 
highly pathogenic H5N1 and pH1N1 influenza viruses. The MVA-based vaccines proved to be immunogenic and 
induced broad-protective immune responses. MVA has favourable properties for the production, storage and use as a 
pandemic influenza vaccine and further clinical development seems warranted. 
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1. Introduction 
Since 2003 more than 500 human cases of infection with highly pathogenic avian influenza (HPAI) 
viruses of the H5N1 subtype have been reported. Approximately 60% of these cases had a fatal outcome 
[2]. Since these viruses continue to circulate and cause infections of humans it is feared they may adapt to 
their new host by accumulating mutations or by reassortment with human influenza viruses, become 
transmissible from human-to-human and cause a new influenza pandemic. Several antigenically distinct 
clades of H5N1 HPAIs have been identified. Thus, to mitigate the impact of a future pandemic caused by 
influenza H5N1 viruses, ideally safe and effective vaccines are used that induce cross-clade immunity. In 
addition, these vaccines should become available in a timely fashion and in sufficient quantities. The 
latter is a key issue and was exemplified during the 2009 influenza pandemic caused by influenza 
A/H1N1 viruses that were of swine origin. Although effective vaccines, with and without an adjuvant 
were produced, they arrived too late and in most countries after the peak of the pandemic[3]. Clearly there 
is room for improvement to accelerate the availability of pandemic influenza vaccines.  
The development of novel generations of influenza vaccines and vaccine production platforms may aid 
in a more rapid arrival of vaccines in the face of a pandemic outbreak.  For example, recombinant viral 
vector vaccines, based on adenovirus and poxvirus expressing selected influenza virus genes have been 
shown to be immunogenic and to afford protection against infection with influenza A/H5N1 viruses in 
animal models.  We have a special interest in the replication deficient modified vaccinia virus Ankara 
(MVA) as a vector for the delivery of influenza antigens and as a vaccine production platform[1, 4]. 
MVA was obtained after serial passage in chicken embryo fibroblasts and originally developed as a safe 
vaccine against smallpox. It was administered to > 120.000 subjects without significant side effects. In 
addition, administration of MVA to immunocompromised subjects is safe and does not result in systemic 
disease often seen with the administration of wild type replication competent vaccinia virus. Other 
favourable properties include its good stability that would allow stockpiling of the vaccine and its good 
immunogenicity that was demonstrated for a number of viral and tumor antigens [5-6]. 
Here we present data that we have obtained with candidate MVA-based (pandemic) influenza vaccines 
in animal models. 
2. Preclinical evaluation of MVA-based influenza vaccines 
2.1. Evaluation of a candidate MVA-based H5N1 vaccine in mice 
Two recombinant MVA were produced expressing the HA gene of influenza viruses A/Hong 
Kong/156/97 (MVA-HA-HK/97) or A/Vietnam/1194/04 (MVA-HA-VN/04) as described previously [7]. 
These two influenza viruses belong to two antigenically different clades of influenza A/H5N1 viruses. 
C57BL/6 mice were vaccinated twice intramuscularly with a dose of 108 pfu and a time interval of four 
weeks. Vaccination with these two vaccine preparations induced antibody responses that cross-reacted 
with heterologous H5N1 strains to a limited extent. Four weeks after the last immunization the mice were 
infected with a lethal dose of influenza A/H5N1 viruses A/Hong Kong/156/97 (clade 0),  
A/Vietnam/1194/04   (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the cross protective potential of 
the immune response that was induced. Both MVA vaccine preparations afforded protection against the 
homologous virus both in terms of the development of clinical signs and virus replication in the lungs 
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(Table 1). Immunization with MVA-HA-HK/97 also provided clinical protection against infection with 
A/Vietnam/1194/04, but could not fully prevent virus replication. Furthermore, this vaccine preparation 
did not afford protection against infection with influenza virus A/Indonesia/5/05. In contrast, the use of 
MVA-HA-VN/04 afforded clinical protection against infection with the two heterologous virus A/Hong 
Kong/156/97 and A/Indonesia/5/05 and reduced virus replication of these two viruses considerably. 
Because vaccine candidate MVA-HA-VN/04 induced more broadly protective immune responses, this 
vaccine preparation was selected for further studies  
2.2. Evaluation of a candidate MVA-based H5N1 vaccine in macaques 
Since with MVA-HA-VN/04 promising results were obtained in mice, we wished to test this vaccine 
candidate also in non-human primates. To this end, cynomolgus macaques (macaca fascicularis) were 
vaccinated twice with a dose of 108.5 pfu of MVA-HA-VN/04 with an interval of four weeks. Control 
animals received the empty MVA vector or were mock-vaccinated with PBS. Also in this species, MVA-
HA-VN/04 was immunogenic and the antibodies that were induced to the HA of influenza virus 
A/Vietnam/1194/04 cross reacted with antigenically distinct influenza virus A/Indonesia/5/05 of clade 2.1 
to some extent [8]. Upon challenge infection with the homologous virus A/VN/1194/04 or the 
antigenically distinct virus A/Indonesia/5/05 four weeks after the last vaccination, control animals 
developed clinical signs and severe broncho-interstitial pneumonia and high virus titers were found in the 
upper respiratory tract and lungs of these animals. In contrast, the MVA-HA-VN/04 vaccinates macaques 
were fully protected from infection with both viruses and did not show signs of illness and respiratory 
specimens including lung tissue tested negative by virus isolation and detection of virus-infected cells in 
situ by immunohistochemistry (Table 1).      
Table 1. Summary of the preclinical evaluation of MVA-based influenza vaccines 
Recombinant MVA 
expressing HA gene 
of influenza virus 
Dose
(PFU) 







A/Hong Kong/156/97 2x 108  H5N1 Mice A/HK/156/97 Yes/yes [7] 
(clade 0)    A/VN/1194/04 Yes/no  
    A/Ind/5/05 No/no   
A/Vietnam/1194/04 2x 108 H5N1 Mice A/HK/156/97 Yes/partially [7] 
(clade 1)    A/VN/1194/04 Yes/yes  
    A/Ind/5/05 Yes/partially  
A/Vietnam/1194/04 2x 3.108 H5N1 Macaques A/VN/1194/04 Yes/Yes [8] 
    A/Ind/5/05 Yes/Yes  
A/Vietnam/1194/04 2x 105 H5N1 Mice A/VN/1194/04 Yes/Yes [9] 
 2x 105   A/Ind/5/05 Yes/yes  
 1x 108 H5N1 Mice A/VN/1194/04 Yes/partially [9] 
 1x 108   A/Ind/5/05 Yes/partially  
A/California/4/09 1x 3.108 pH1N1 Ferrets A/NL/602/09 Partially/partially [10] 
 2x 3.108   A/NL/602/09 Yes/partially  
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2.3. Dose-sparing and evaluation of single immunization regimen in mice 
To stretch the number of individuals that can be vaccinated with any given amount of vaccine doses 
that can be produced, it would be desirable if dose-sparing can be achieved with a pandemic influenza 
vaccine. Furthermore, an emerging pandemic may impose serious time pressure and protective immunity 
should be induced as quickly as possible, preferably after a single immunization. Therefore we wished to 
assess the minimal requirements necessary for the induction of protective immune responses against 
homologous and heterologous H5N1 influenza viruses by an MVA-based H5N1 vaccine. To this end, 
C57BL/6 mice were immunized once or twice with MVA-HA-VN/04 using a wide range of doses and 
subsequently these animals were infected with a lethal dose of the homologous strain A/Vietnam/1194/04 
or the heterologous strain A/Indonesia/5/05 [9]. After two immunizations with a dose of 105 pfu the mice 
were fully protected from developing clinical signs, which correlated with > 6 log reduction of lung virus 
titers detected on day 4 post inoculation with both viruses, compared to mice in control groups. Also a 
single immunization with a dose of 108 pfu of MVA-HA-VN/04 afforded substantial protection against 
infection with both viruses and prevented the induction of clinical signs although virus replication in the 
lungs could not be completely prevented. Nevertheless a reduction in lung virus titers of approximately 5 
logs was achieved after infection with homologous strain A/Vietnam/1194/04 and the heterologous 
strains A/Indonesia/5/05.    
2.4. Evaluation of a candidate MVA-based pH1N1 vaccine in ferrets 
After the pandemic outbreak in 2009 with influenza virus of the H1N1 subtype we wanted to 
investigate the feasibility to develop a pH1N1 vaccine based on the MVA technology. The HA gene of 
influenza virus A/California/4/09 was cloned into a MVA shuttle plasmid and recombinant virus MVA-
HA-CA/09 was obtained through homologous recombination [10]. This vaccine preparation was tested in 
ferrets which are susceptible to infection with a variety of influenza viruses, and which are considered to 
constitute a good animal model for the infection of humans. Two ferret pH1N1 models were established 
in our laboratory recently [11-12]. For the present study animals were infected by the intratracheal route 
[12]. First, ferrets were immunized once or twice with 108.5 of MVA-HA-CA/09. A single immunization 
induced modest virus-specific antibodies titers which were boosted by the second vaccination. Four 
weeks after the last vaccination the animals were inoculated with 106 TCID50 of pH1N1 virus 
A/Netherlands/602/09 by the intratracheal route. Despite this harsh challenge infection, ferrets that 
received a single immunization displayed reduced areas of consolidation in the lung compared to control 
animals that received the empty MVA vector or were mock-vaccinated with PBS. In the animals 
vaccinated once with MVA-HA-CA/09 the lung virus titers were tenfold lower than in the control 
animals. A second immunization had a beneficial effect on the outcome of the challenge infection. In 
these animals the loss of bodyweight caused by infection was significantly reduced, so was the 
development of lesions in the lungs.  The reduction of clinical signs and histopathological changes 
correlated with a reduction in lung virus titers, which were on average 4 logs lower than in mock-
vaccinated control animals [10]. 
3. Conclusions 
The recent studies with recombinant MVA expressing the HA gene of highly pathogenic A/H5N1 
influenza viruses or the HA gene of 2009 pandemic H1N1 virus indicate that robust protective immunity 
can be induced with these candidate vaccine against infections that otherwise would have been fatal. In all 
cases vaccination reduced virus replication in the lungs, prevented the development of clinical signs and 
histopathological lesions in the lungs. Protection correlated with the induction of influenza virus 
neutralizing antibodies. In the case of H5N1 viruses, these antibodies cross-reacted to some extent with 
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antigenically distinct viruses from other clades of H5N1 viruses and protection was achieved against 
these heterologous viruses. The induction of cross-clade immunity is a favorable property of 
(pre)pandemic H5N1 vaccines, since it can not be predicted which strain eventually may cause a 
pandemic outbreak.   In all animal species tested, vaccination with MVA-based vaccines was very well 
tolerated, without any signs of side effects. Collectively, we conclude that vaccines based on the MVA 
technology are immunogenic and able to induce robust protective immunity. In combination with a 
number of favorable properties such as good stability and ease of manufacturing in chicken embryo 
fibroblasts the MVA technology holds promise as a production platform for pandemic influenza vaccines. 
Based on the promising results obtained in various animal species, including non-human primates further 
clinical development of MVA-based influenza vaccines is warranted. 
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